CO2023000604A2 - Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity - Google Patents
Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activityInfo
- Publication number
- CO2023000604A2 CO2023000604A2 CONC2023/0000604A CO2023000604A CO2023000604A2 CO 2023000604 A2 CO2023000604 A2 CO 2023000604A2 CO 2023000604 A CO2023000604 A CO 2023000604A CO 2023000604 A2 CO2023000604 A2 CO 2023000604A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- activity
- diseases associated
- aberrant
- interleukin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
Abstract
RESUMEN La presente invención se refiere a la medicina y se refiere al tratamiento de enfermedades asociadas con la actividad aberrante de la interleucina-6 y el desarrollo del síndrome de liberación de citocinas (tormenta de citocinas), preferentemente el tratamiento de COVID-19, así como otras enfermedades complicadas por la actividad aberrante de interleucina-6 y el desarrollo del síndrome de liberación de citocinas, utilizando el compuesto 1-(2-(1-metil-1H-imidazol-4-il)etil)piperidina-2,6-diona (fórmula I). La invención proporciona la creación de un nuevo fármaco eficaz para el tratamiento de enfermedades asociadas con el desarrollo del síndrome de liberación de citocinas.ABSTRACT The present invention relates to medicine and relates to the treatment of diseases associated with aberrant interleukin-6 activity and the development of cytokine release syndrome (cytokine storm), preferably the treatment of COVID-19, as well as as other diseases complicated by aberrant interleukin-6 activity and development of cytokine release syndrome, using the compound 1-(2-(1-methyl-1H-imidazol-4-yl)ethyl)piperidine-2,6 -dione (formula I). The invention provides for the creation of a new effective drug for the treatment of diseases associated with the development of cytokine release syndrome.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2020121363A RU2774928C2 (en) | 2020-06-26 | Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6 | |
PCT/RU2021/050170 WO2021262040A1 (en) | 2020-06-26 | 2021-06-18 | Use of a glutarimide derivative for treating diseases associated with aberrant interleukin-6 activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2023000604A2 true CO2023000604A2 (en) | 2023-01-26 |
Family
ID=79281595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2023/0000604A CO2023000604A2 (en) | 2020-06-26 | 2023-01-19 | Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity |
Country Status (6)
Country | Link |
---|---|
CN (1) | CN115803026A (en) |
BR (1) | BR112022026356A2 (en) |
CL (1) | CL2022003725A1 (en) |
CO (1) | CO2023000604A2 (en) |
MA (1) | MA58653B1 (en) |
WO (1) | WO2021262040A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023177329A1 (en) * | 2022-03-18 | 2023-09-21 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Use of 1-(2-(1н-imidazole-4-yl)ethyl)piperidine-2,6-dione to treat cough caused by viral infections |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2112716A1 (en) * | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Biphenylyl-butyric acid derivs. - anti phlogistics |
DE10002509A1 (en) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | New substituted glutarimide derivatives are IL-12 antagonists, are useful as immunomodulators and for the treatment of angiopathy, hematological or oncological disorders |
UA115431C2 (en) * | 2011-10-11 | 2017-11-10 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Use of glutaryl histamine to treat respiratory tract infections |
CN102432544B (en) * | 2011-11-17 | 2014-05-21 | 天津医科大学 | 5-substituted benzyl methylene imidazole alkyl-2,4-diketone derivative and application thereof |
EA032951B1 (en) * | 2013-04-12 | 2019-08-30 | Общество С Ограниченной Ответственностью "Рсв Терапевтикс" | Glutarimide derivative, use thereof, pharmaceutical composition based thereon, process for preparing same |
RU2552929C1 (en) * | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Pharmaceutical composition, containing derivatives of glutarimides, and their application for treatment of eosinophilic diseases |
US10739353B2 (en) * | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
GEP20227402B (en) * | 2017-09-07 | 2022-08-10 | Valenta Intellekt Ltd | Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines |
AU2021257439A1 (en) * | 2020-04-13 | 2022-12-15 | University Health Network | Methods for treating cytokine release syndrome |
EP4144728A4 (en) * | 2020-04-30 | 2023-08-23 | Shanghaitech University | Heterocycle and glutarimide skeleton-based compound and applications thereof |
-
2021
- 2021-06-18 MA MA58653A patent/MA58653B1/en unknown
- 2021-06-18 BR BR112022026356A patent/BR112022026356A2/en unknown
- 2021-06-18 CN CN202180044905.7A patent/CN115803026A/en active Pending
- 2021-06-18 WO PCT/RU2021/050170 patent/WO2021262040A1/en active Application Filing
-
2022
- 2022-12-22 CL CL2022003725A patent/CL2022003725A1/en unknown
-
2023
- 2023-01-19 CO CONC2023/0000604A patent/CO2023000604A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA58653A1 (en) | 2023-07-31 |
BR112022026356A2 (en) | 2023-01-17 |
CL2022003725A1 (en) | 2023-05-19 |
RU2020121363A (en) | 2021-12-27 |
MA58653B1 (en) | 2024-02-29 |
WO2021262040A1 (en) | 2021-12-30 |
RU2020121363A3 (en) | 2021-12-27 |
CN115803026A (en) | 2023-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001625A1 (en) | Pyrazolyl derivatives useful as anti-cancer agents | |
PA8635201A1 (en) | USE OF SUBSTITUTED QUINOLINE DERIVATIVES FOR THE TREATMENT OF DRUG RESISTANT MICOBACTERIAL DISEASES | |
UY32462A (en) | NEW BIFENYLL DERIVATIVES FOR HEPATITIS C 644 VIRUS INFECTION TREATMENT | |
MA37405A1 (en) | Heterocyclyl compounds | |
AR060536A1 (en) | GLUCOCORTICOID RECEPTOR AGONIST AND PHARMACEUTICAL COMPOSITIONS | |
ECSP088973A (en) | IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHETIC KINASE GLYCOGEN (GSK3) | |
DOP2012000025A (en) | PIRIDINE AND PIRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | |
ECSP066302A (en) | OMEGA-CARBOXIARIL-DIFENIL-UREA REPLACED WITH FLUORINE FOR THE TREATMENT AND PREVENTION OF DISEASES AND AFFECTIONS | |
PE20130009A1 (en) | HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS | |
CO6270360A2 (en) | NON-BASIC ANTAGONISTS OF THE RECEIVER OF THE CONCENTRATING HORMONE OF MELANINE 1 AND PROCEDURES | |
AR075729A1 (en) | DERIVATIVES OF BENZOFURANILO, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF OBESITY AND / OR DIABETES. | |
CL2015002608A1 (en) | Amino-pyrazole compound and related medicinal uses. | |
CO6311077A2 (en) | DERIVATIVES OF 1- (4-HYDROXY-PHENYL) -1H-INDOL AS NEW NOVEDOS OF STERROGEN RECEIVER | |
AR067390A1 (en) | IMISMAZED TRISUSTITUTES, A PROCESS FOR THEIR DEVELOPMENT, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATIONED BY THE ANTAGONISM OF CCR RECEPTORS | |
CO7131360A2 (en) | Novel substituted cyclic n-pyridinyl amides as kinase inhibitors | |
CY1105631T1 (en) | SUBSTITUTED CARBOSTYRYL DERIVATIVES AS 5-HT1A RECEPTOR SUBTYPE AGENTS | |
DOP2024000039A (en) | QUINOLINE DERIVATIVES AS ALFA4BETA7 INTEGRIN INHIBITORS | |
CO2023000604A2 (en) | Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity | |
NI200700032A (en) | ARILSULFONYLESTILBEN DERIVATIVES FOR INSOMNIA TREATMENT AND RELATED AFFECTIONS | |
EA201001857A1 (en) | PHARMACEUTICAL MEDICINE FORM FOR IMMEDIATE RELEASE OF INDOLINON DERIVATIVE | |
BR112017003242A2 (en) | compound, methods for treating virus infection and for the manufacture of a medicament, pharmaceutical composition, and use of a compound. | |
CL2022001337A1 (en) | Pyridopyrimidinone derivatives as ahr antagonists | |
EA202091604A1 (en) | INHIBITION OF THE ION CHANNEL A1 WITH A TRANSITOR RECEPTOR POTENTIAL | |
UY32829A (en) | DERIVATIVES OF 3-HETEROARIL-METIL-IMIDAZO- [1,2-B] -PIRIDIDAZIN - 6 -ILO | |
MX2020004025A (en) | Epidermal growth factor receptor inhibitors. |